Search results
Results from the WOW.Com Content Network
Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the patent application.
The patent application at the center of the case was filed by Novartis in India in 1998, after India had agreed to enter the World Trade Organization and to abide by worldwide intellectual property standards under the TRIPS agreement. As part of this agreement, India made changes to its patent law; the biggest of which was that prior to these ...
The patent application [65] [79] claimed the final form of Gleevec (the beta crystalline form of imatinib mesylate). [80]: 3 In 1993, during the time India did not allow patents on products, Novartis had patented imatinib, with salts vaguely specified, in many countries but could not patent it in India.
Grover led the Lawyers Collective court case against Novartis regarding an interpretation of Agreement on Trade-Related Aspects of Intellectual Property Rights which would determine the patent status of antiretroviral drugs in India. The result of the case was that the Lawyers Collective prevailed and certain drugs became ineligible for ...
Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005. But now, Novartis discovered it accidentally overpaid by nearly $210 ...
(Reuters) -Novartis failed to convince a federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according ...
Novartis had filed a patent for Glivec in 1997. [30] An exclusive marketing right was also granted for Novartis in 2003 and the application were approved in 2005 . [ 30 ] In 2013, the Supreme Court of India upheld the rejection of the patent application of Glivec by Novartis , [ 31 ] ending the 10-years battle between the proprietary drug ...
For premium support please call: 800-290-4726 more ways to reach us